At the news
? BULLISHIMPACT 7/10 PRESS-RELEASE filed Apr 13, 2026 at 08:00 ET
Septerna announced the dosing of the first participants in its Phase 1 trial of SEP-479, an oral small molecule PTH1R agonist for hypoparathyroidism. Clinical data is expected in late 2026 or early 2027. This marks a key milestone in advancing a potential first-in-class oral therapy for a rare endocrine disorder.
- Septerna has initiated dosing in the Phase 1 clinical trial of SEP-479 for hypoparathyroidism.
- The trial is a single- and multiple-ascending dose study in healthy volunteers, evaluating safety, tolerability, PK, and PD.
- Up to 150 participants will be enrolled; data readout expected in late 2026 or early 2027.
- SEP-479 is a potent oral small molecule agonist targeting the PTH1R receptor, aiming to provide once-daily dosing.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access